Deep vein thrombosis: Pathogenesis, diagnosis, and medical management

Jonathan Stone, Patrick Hangge, Hassan Albadawi, Alex Wallace, Fadi Shamoun, M. Grace Knuttien, Sailendra Naidu, Rahmi Oklu

Research output: Contribution to journalReview articlepeer-review

63 Scopus citations


Deep vein thrombosis (DVT) is a major preventable cause of morbidity and mortality worldwide. Venous thromboembolism (VTE), which includes DVT and pulmonary embolism (PE), affects an estimated 1 per 1,000 people and contributes to 60,000-100,000 deaths annually. Normal blood physiology hinges on a delicate balance between pro- and anti-coagulant factors. Virchow's Triad distills the multitude of risk factors for DVT into three basic elements favoring thrombus formation: Venous stasis, vascular injury, and hypercoagulability. Clinical, biochemical, and radiological tests are used to increase the sensitivity and specificity for diagnosing DVT. Anticoagulation therapy is essential for the treatment of DVT. With few exceptions, the standard therapy for DVT has been Vitamin K-antagonists (VKAs) such as warfarin with heparin or fractionated heparin bridging. More recently, a number of large-scale clinical trials have validated the use of direct oral anticoagulants (DOACs) in place of warfarin in select cases. In this review, we summarize the pathogenesis, diagnosis, and medical management of DVT, with particular emphasis on anticoagulation therapy and the role of DOACs in the current treatment algorithm.

Original languageEnglish (US)
Pages (from-to)S276-S284
JournalCardiovascular Diagnosis and Therapy
StatePublished - Dec 1 2017


  • Anticoagulants
  • Deep vein thrombosis (DVT)
  • Direct oral anticoagulants (DOACs)
  • Vitamin K-antagonists (VKAs)
  • Warfarin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Deep vein thrombosis: Pathogenesis, diagnosis, and medical management'. Together they form a unique fingerprint.

Cite this